These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24379617)

  • 21. Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection.
    Grebely J; Hellard M; Applegate T; Petoumenos K; Yeung B; Feld JJ; Rawlinson W; Lloyd AR; George J; Kaldor JM; Dore GJ; Matthews GV;
    AIDS; 2012 Aug; 26(13):1653-61. PubMed ID: 22555168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
    Mangia A; Thompson AJ; Santoro R; Piazzolla V; Tillmann HL; Patel K; Shianna KV; Mottola L; Petruzzellis D; Bacca D; Carretta V; Minerva N; Goldstein DB; McHutchison JG
    Gastroenterology; 2010 Sep; 139(3):821-7, 827.e1. PubMed ID: 20621700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population.
    Martínez-Gómez LE; Chávez-Tapia NC; Burguete-García AI; Aguilar-Olivos N; Madrid-Marina V; Román-Bahena M; Orbe-Orihuela C; Misael U; Méndez-Sánchez N
    Ann Hepatol; 2012; 11(6):876-81. PubMed ID: 23109451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.
    De Nicola S; Aghemo A; Rumi MG; Galmozzi E; Valenti L; Soffredini R; De Francesco R; Prati GM; D'Ambrosio R; Cheroni C; Donato MF; Colombo M
    Hepatology; 2012 Feb; 55(2):336-42. PubMed ID: 21932415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients.
    El Awady MK; Bader El Din NG; Tabll A; El Hosary Y; Abdel Aziz AO; El Khayat H; Salama M; Abdelhafez TH
    World J Gastroenterol; 2013 Jan; 19(2):290-8. PubMed ID: 23345953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of response to sofosbuvir-based therapy using serum interleukin-12 and single nucleotide polymorphism of the interleukin 28B gene as predictive factors in HCV positive genotype-4 patients.
    Mohamed Abdelnajid D; Elmowafy AY; Rostaing L; Elrakaiby MT
    Medicine (Baltimore); 2023 Jul; 102(28):e34125. PubMed ID: 37443472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.
    Hayes CN; Kobayashi M; Akuta N; Suzuki F; Kumada H; Abe H; Miki D; Imamura M; Ochi H; Kamatani N; Nakamura Y; Chayama K
    Gut; 2011 Feb; 60(2):261-7. PubMed ID: 21068134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IL-28B polymorphisms correlated with treatment response in HCV-4 mono-infected patients: a meta-analysis.
    Liu T; Sha K; Yang L; Wang Y; Zhang L; Liu X; Yang F
    PLoS One; 2014; 9(3):e91316. PubMed ID: 24642705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of interleukin-28B rs12979860 and rs8099917 polymorphisms with sustained viral response in hepatitis C virus genotype 1 and 3 infected patients from the Indian subcontinent.
    Ranjan P; Fletcher GJ; Radhakrishnan M; Sivakumar J; Premkumar PS; Goel A; Zachariah UG; Abraham P
    Indian J Med Microbiol; 2016; 34(3):335-41. PubMed ID: 27514956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4.
    Rivero-Juárez A; Camacho Espejo A; Perez-Camacho I; Neukam K; Caruz A; Mira JA; Mesa P; García-Lázaro M; Torre-Cisneros J; Pineda JA; Rivero A
    J Antimicrob Chemother; 2012 Jan; 67(1):202-5. PubMed ID: 21990051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.
    Neukam K; Camacho A; Caruz A; Rallón N; Torres-Cornejo A; Rockstroh JK; Macías J; Rivero A; Benito JM; López-Cortés LF; Nattermann J; Gómez-Mateos J; Soriano V; Pineda JA
    J Hepatol; 2012 Apr; 56(4):788-94. PubMed ID: 22173157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection.
    Grebely J; Petoumenos K; Hellard M; Matthews GV; Suppiah V; Applegate T; Yeung B; Marks P; Rawlinson W; Lloyd AR; Booth D; Kaldor JM; George J; Dore GJ;
    Hepatology; 2010 Oct; 52(4):1216-24. PubMed ID: 20803561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study of Interleukin 28B rs12979860 and rs8099917 Polymorphisms and T-helper 1 Response in Hepatitis C Virus Patients.
    Ea R; Aa G; Ag ES; Ma A
    Egypt J Immunol; 2015 Jun; 22(2):57-68. PubMed ID: 28502145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection].
    Pár A; Pár G; Tornai I; Szalay F; Várszegi D; Fráter E; Papp M; Lengyel G; Fehér J; Varga M; Gervain J; Schuller J; Nemes Z; Péterfi Z; Tusnádi A; Hunyady B; Haragh A; Szinku Z; Pálinkás L; Berki T; Vincze A; Kisfali P; Melegh B
    Orv Hetil; 2013 Aug; 154(32):1261-8. PubMed ID: 23916907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response to treatment in Brazilian patients with chronic hepatitis C is associated with a single-nucleotide polymorphism near the interleukin-28B gene.
    Grandi T; da Silva CM; Amaral KM; Picon PD; Costi C; da Fré NN; Fiegenbaum M; Niel C; Rossetti ML
    Mem Inst Oswaldo Cruz; 2013 Feb; 108(1):48-53. PubMed ID: 23440114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin 28B polymorphisms and therapy response in Egyptian hepatitis C genotype-4 patients.
    Gouda HM; El-Saadany ZA; Foad NB; Salama RM
    DNA Cell Biol; 2014 Sep; 33(9):642-6. PubMed ID: 24999753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.
    Umemura T; Ota M; Katsuyama Y; Wada S; Mori H; Maruyama A; Shibata S; Nozawa Y; Kimura T; Morita S; Joshita S; Komatsu M; Matsumoto A; Kamijo A; Kobayashi M; Takamatsu M; Yoshizawa K; Kiyosawa K; Tanaka E
    Hum Immunol; 2014 Aug; 75(8):822-6. PubMed ID: 24929144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of IL28B for chronic hepatitis C treatment toward personalized medicine.
    Matsuura K; Watanabe T; Tanaka Y
    J Gastroenterol Hepatol; 2014 Feb; 29(2):241-9. PubMed ID: 24325405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.